Biocon Signs Brazil Partnerships With Bahiafarma and Bionovis for Local Production and Commercialisation of Pertuzumab
Biocon has signed a long-term partnership agreement with Brazilian pharmaceutical organisations Bahiafarma and Bionovis for the production and commercialisation of Pertuzumab, securing access to Brazil's public healthcare market under a 10-year Productive Development Partnership programme for the HER2-positive breast cancer therapy.
The consortium comprising Biocon, Bahiafarma and Bionovis has received 100% allocation under Brazil's 10-year Productive Development Partnership, or PDP, programme for Pertuzumab.
The arrangement gives the consortium exclusive access under the programme to Brazil's public healthcare market, which represents approximately 70% of the country's demand for Pertuzumab.
For Biocon, the agreement creates a decade-long commercial opportunity in one of Latin America's largest healthcare markets while also establishing a pathway for the phased localisation of Pertuzumab production in Brazil over the medium to long term.
Biocon will receive milestone payments as well as a share of revenue generated from the Brazilian PDP opportunity during the 10-year period. The company has not disclosed the financial value of the contract or the expected revenue contribution.
Biocon Secures 10-Year Pertuzumab Opportunity in Brazil
Biocon announced the partnership on September 8, 2026, describing it as an important step in expanding the production and commercialisation of Pertuzumab in Brazil.
Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer.
The therapy is currently not manufactured locally in Brazil and represents a significant expenditure for the country's public healthcare system, known as Sistema Único de Saúde, or SUS.
The new arrangement is designed to address both requirements: improving long-term access to the medicine while developing domestic capabilities to manufacture the complex biologic.
Consortium Receives 100% Allocation Under Brazil's PDP
The commercial significance of the agreement comes from the consortium receiving:
100% allocation under the 10-year Pertuzumab PDP programme.
Brazil's PDP framework is designed to combine public procurement with technology transfer and localisation.
Rather than relying indefinitely on imported medicines, the programme creates partnerships between technology providers, local biotechnology companies and public pharmaceutical institutions.
The Pertuzumab agreement therefore extends beyond a conventional export contract.
It establishes a framework under which the product will initially be supplied while manufacturing capabilities are progressively transferred and localised in Brazil.
Public Healthcare Market Represents Around 70% of Demand
The PDP gives the Biocon-Bahiafarma-Bionovis consortium access to Brazil's public healthcare market for Pertuzumab.
That market represents approximately:
70% of the country's total demand for the therapy.
Brazil's SUS is one of the world's largest publicly funded healthcare systems and provides healthcare services to a substantial portion of the country's population.
Securing access through the PDP therefore gives Biocon exposure to a large institutional oncology market rather than relying exclusively on private-sector pharmaceutical sales.
Biocon Will Receive Milestone Payments and Revenue Share
The commercial structure includes two principal components for Biocon.
The company will receive:
milestone payments
and:
a share of revenues generated through the Brazil PDP opportunity.
These payments will occur over the 10-year programme.
Biocon has not disclosed the size of individual milestones, the revenue-sharing percentage or the potential aggregate value of the contract.
The absence of those figures means the agreement's immediate financial impact cannot be reliably quantified from the announcement alone.
Its strategic value is clearer because of its duration, market allocation and localisation framework.
Pertuzumab Production Will Be Localised in Phases
One of the most important elements of the partnership is the planned localisation of Pertuzumab production.
Biocon said the product will undergo:
phased localisation in Brazil over the medium to long term.
The transition is expected to involve technology and manufacturing capabilities being progressively established within the Brazilian pharmaceutical ecosystem.
Complex biologics require sophisticated production processes, quality systems and technical expertise, making localisation substantially more demanding than transferring production of many conventional small-molecule medicines.
The programme is therefore intended to build sustainable domestic capability rather than merely package an imported medicine locally.
Bahiafarma Provides Public-Sector Manufacturing Link
Bahiafarma is a public pharmaceutical laboratory owned by the State of Bahia.
Its activities include pharmaceutical research, technological development, innovation and the production and supply of medicines and healthcare products.
The organisation is particularly focused on supplying Brazil's SUS.
Within the Pertuzumab partnership, Bahiafarma provides an important connection to Brazil's public pharmaceutical infrastructure and the government's broader objective of strengthening domestic production of strategically important medicines.
Bionovis Brings Brazilian Biologics Expertise
Bionovis is a Brazilian biotechnology company specialising in:
complex biological medicines,
biosimilars,
technology transfer,
and local biopharmaceutical manufacturing.
The company has developed partnerships with international pharmaceutical groups to bring biologic manufacturing technologies into Brazil.
For the Pertuzumab programme, Bionovis provides local biotechnology and manufacturing expertise that complements Biocon's development and global production capabilities and Bahiafarma's role within the public pharmaceutical system.
Partnership Combines Three Complementary Capabilities
The structure of the consortium reflects the requirements of Brazil's localisation model.
Biocon contributes:
biopharmaceutical development,
manufacturing expertise,
and Pertuzumab technology.
Bionovis contributes:
local biologics manufacturing capabilities
and:
technology-transfer experience.
Bahiafarma contributes:
public-sector pharmaceutical infrastructure
and:
integration with Brazil's healthcare ecosystem.
The combination is designed to create a pathway from international supply toward increasingly local production.
Pertuzumab Targets HER2-Positive Breast Cancer
Pertuzumab is used in the treatment of:
HER2-positive breast cancer.
HER2-positive cancers have elevated levels of human epidermal growth factor receptor 2, a protein that can promote cancer-cell growth.
HER2-targeted biologic therapies have become important components of treatment for eligible patients.
However, biologic medicines can be expensive to manufacture and procure, creating significant cost pressures for public healthcare systems seeking to provide broad patient access.
Brazil has identified Pertuzumab as one of the medicines where local production capability could help strengthen long-term supply and healthcare-system resilience.
Brazil Currently Does Not Manufacture Pertuzumab Locally
A key reason for the PDP arrangement is that Pertuzumab is:
not currently manufactured in Brazil.
That creates dependence on international supply for an important oncology medicine.
For SUS, the drug also represents significant pharmaceutical expenditure.
Localisation is intended to address both issues by developing domestic manufacturing expertise while maintaining access during the transition.
The programme's success will ultimately depend on effective technology transfer, regulatory compliance, manufacturing quality and the ability to achieve local production at the required scale.
Deal Expands Biocon's Oncology Presence
The agreement strengthens Biocon's international oncology portfolio.
Oncology is one of the company's major therapeutic areas alongside:
diabetes,
obesity,
immunology,
ophthalmology,
cardiovascular disease,
and bone health.
Biocon has built a substantial global business around complex generics and biosimilars, where development and manufacturing capabilities can help reduce the cost of advanced biological therapies.
The Brazilian Pertuzumab programme extends that strategy into a large public oncology network.
Brazil Is Strategically Important for Biocon
Biocon Chief Executive Officer and Managing Director Shreehas Tambe has identified Brazil as an important market for the company.
The group sees partnerships with local organisations as a way to combine its scientific and manufacturing capabilities with domestic healthcare expertise.
That approach can be particularly important in markets where governments are seeking both:
greater medicine access
and:
greater pharmaceutical self-reliance.
Instead of operating solely as an exporter, Biocon can participate in building local manufacturing capacity.
Agreement Supports Brazil's Pharmaceutical Self-Reliance Strategy
Brazil's PDP programme is part of a broader effort to strengthen the country's Health Economic-Industrial Complex.
The policy seeks to reduce vulnerability to imported strategic healthcare products while developing:
local technology,
manufacturing,
specialised employment,
and pharmaceutical expertise.
Biological medicines are particularly relevant because their manufacturing processes are technically complex and require substantial infrastructure.
A successful Pertuzumab technology transfer could therefore have value beyond the individual medicine by strengthening the country's broader biologics manufacturing capabilities.
Bahiafarma Sees Partnership as Strategic Public-Health Project
Bahiafarma Chief Executive Ceuci Nunes has characterised the partnership as a strategic project for public health.
For Bahiafarma, the programme provides an opportunity to incorporate highly complex pharmaceutical technology and strengthen Brazil's capacity to produce medicines considered important for SUS.
That objective is central to the PDP framework.
The programme is designed not merely to procure products but to create a domestic capability that remains valuable after technology transfer progresses.
Bionovis Focuses on Technology Transfer and Local Manufacturing
Bionovis CEO Odnir Finotti has linked the agreement to Brazil's policy of expanding access to complex biological medicines while strengthening productive autonomy.
The company has experience working with international pharmaceutical groups through technology-transfer arrangements.
For Bionovis, the Biocon partnership adds another complex biologic to that localisation strategy.
The programme could also support specialised employment and technical expertise as manufacturing shifts progressively into Brazil.
Long-Term Contract Provides Greater Commercial Visibility
The:
10-year duration
is particularly important for Biocon.
Pharmaceutical localisation programmes require substantial time because technology transfer, manufacturing scale-up, regulatory processes and quality validation cannot be completed immediately.
A decade-long framework gives the partners a longer commercial horizon over which to undertake those investments.
For Biocon, milestone payments and revenue participation provide financial incentives throughout the programme while localisation progresses.
Deal Is More Than a Conventional Supply Contract
Although the arrangement includes long-term supply, describing it only as a supply agreement understates its scope.
The transaction combines:
commercialisation,
public procurement access,
technology transfer,
and phased local production.
That structure makes the agreement strategically different from simply shipping finished Pertuzumab from an overseas manufacturing facility into Brazil.
The intended endpoint is a more locally integrated supply chain.
Localisation Could Improve Supply Resilience
Domestic manufacturing can potentially reduce some of the vulnerabilities associated with depending entirely on imported medicines.
Global pharmaceutical supply chains can be disrupted by:
manufacturing interruptions,
logistics constraints,
geopolitical developments,
and unexpected increases in demand.
Local capacity does not eliminate these risks, because pharmaceutical manufacturing still depends on international raw materials and specialised equipment in many cases.
However, it can diversify the supply chain and strengthen domestic technical capabilities.
Affordability Remains Important for Biologic Therapies
Complex biologic therapies have transformed treatment in several diseases but can impose substantial costs on healthcare systems.
Biosimilar competition and local manufacturing can potentially improve affordability and expand access, subject to regulatory approval, procurement structures and sustainable production economics.
For Biocon, this is closely aligned with its broader strategy of developing affordable biologic medicines for global markets.
The Brazil partnership provides an opportunity to apply that model within a large public healthcare system.
Biocon Has Built a Broad Global Biosimilars Portfolio
Biocon says it has commercialised:
12 biosimilar products
and more than:
30 generic formulations
globally.
Its research and development pipeline includes more than:
20 biosimilar assets, along with GLP-1 peptides and other complex generics.
The company operates in more than:
120 countries
and has an international manufacturing, research and commercial network.
That scale gives Biocon experience in navigating different regulatory and healthcare systems as it expands access to complex medicines.
Brazil Deal Demonstrates Local-Partnership Strategy
The Pertuzumab agreement also illustrates how pharmaceutical companies can expand in major emerging markets through local partnerships rather than relying exclusively on wholly owned operations.
For Biocon, working with Bahiafarma and Bionovis gives it access to:
public-sector relationships,
domestic manufacturing expertise,
and local regulatory knowledge.
For the Brazilian partners, Biocon provides access to established biologics technology and global manufacturing experience.
The model aligns the commercial interests of the participants with Brazil's healthcare-industrial policy.
Financial Impact Will Develop Over Time
The partnership is strategically significant, but investors should distinguish its long-term opportunity from immediate earnings impact.
Biocon has disclosed:
milestone payments,
revenue sharing,
a 10-year duration,
and 100% PDP allocation.
It has not disclosed:
the total contract value,
expected annual revenue,
profit margins,
or the financial size of individual milestones.
The economic contribution will therefore emerge over time as supply, commercialisation and localisation progress.
Conclusion
Biocon's partnership with Bahiafarma and Bionovis gives the Bengaluru-based biopharmaceutical company a significant long-term position in Brazil's market for Pertuzumab while creating a pathway toward local manufacturing of the HER2-positive breast cancer therapy.
The three-member consortium has secured 100% allocation under Brazil's 10-year Productive Development Partnership programme, providing exclusive access under the PDP to the country's public healthcare market, which represents approximately 70% of Brazilian demand for Pertuzumab.
Biocon will receive milestone payments and a share of programme revenues over the 10-year period, although the company has not disclosed the overall financial value of the agreement.
The strategic element is the planned phased localisation of Pertuzumab production in Brazil. Biocon will combine its biopharmaceutical expertise with Bionovis' biologics and technology-transfer capabilities and Bahiafarma's public-sector pharmaceutical role.
With Pertuzumab currently not manufactured locally and representing a significant cost for Brazil's SUS, the partnership links Biocon's international oncology expansion with Brazil's goal of strengthening domestic production of complex medicines.